Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) announces that it has acquired Faeth Therapeutics Inc. (“Faeth”), a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling. The acquisition brings Faeth’s lead asset PIKTOR, a proprietary investigational all-oral combination of serabelisib and sapanisertib that inhibits multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting, into Sensei’s pipeline. Concurrent with the acquisition, Sensei entered into a definitive agreement for the sale of Series B non-voting convertible preferred stock in a private placement financing.
Read the full article: Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200M Concurrent Private Placement //
Source: https://www.businesswire.com/news/home/20260217234993/en/Sensei-Biotherapeutics-Announces-Acquisition-of-Faeth-Therapeutics-and-%24200-Million-Concurrent-Private-Placement